Can nitrofurantoin be prescribed to a patient with chronic hepatitis B virus infection who is receiving tenofovir?

Yes, nitrofurantoin can be safely used in a patient with hepatitis B on tenofovir.

There are no known drug interactions between nitrofurantoin and tenofovir, and no contraindications to using nitrofurantoin in patients with chronic hepatitis B who are virally suppressed on antiviral therapy.

Key Considerations

Drug Interaction Profile

• The provided evidence contains no documentation of interactions between nitrofurantoin and tenofovir (either TDF or TAF formulations)
• Tenofovir's drug interaction profile primarily involves medications affecting renal function or those requiring renal dose adjustment 1
• Nitrofurantoin is primarily renally excreted but does not interfere with nucleos(t)ide analogue metabolism

Hepatotoxicity Concerns with Nitrofurantoin

While nitrofurantoin can be used, you should be aware of its hepatotoxic potential:

• Nitrofurantoin can cause drug-induced liver injury, ranging from mild hepatitis to chronic active hepatitis and even fulminant liver failure 2, 3, 4
• This hepatotoxicity is rare but serious, particularly with prolonged use
• Risk factors include: elderly females, preexisting liver disease, and long-term exposure 4
• The liver injury can be immune-mediated and may not resolve immediately upon drug discontinuation 2

Clinical Algorithm for Safe Use

Before prescribing nitrofurantoin:

1. Verify the patient's hepatitis B is virally suppressed on tenofovir (HBV DNA undetectable)
2. Check baseline ALT/AST levels
3. Assess liver function (if cirrhosis present, use with extreme caution)
4. Consider duration of nitrofurantoin therapy needed

During treatment:

• For short courses (3-7 days): Standard monitoring is sufficient
• For prolonged use (>2 weeks) or prophylaxis: Monitor liver enzymes monthly for the first 3 months, then every 3 months
• Instruct patient to report symptoms of hepatotoxicity (fatigue, abdominal pain, dark urine, jaundice)

Discontinue nitrofurantoin immediately if:

• ALT/AST rise >3× baseline
• Patient develops symptoms of hepatitis
• Any signs of hepatic decompensation

Important Caveats

The main concern is NOT the drug interaction but rather:

• Adding hepatotoxic burden to a patient with underlying liver disease
• Patients with hepatitis B on tenofovir already have baseline liver disease that requires monitoring 5
• Nitrofurantoin's hepatotoxicity risk is independent of the hepatitis B or tenofovir

Consider alternatives if:

• Patient has cirrhosis (Child-Pugh B or C)
• History of drug-induced liver injury
• Baseline transaminases are elevated
• Need for long-term prophylactic therapy

Renal Function Monitoring

Since both medications are renally cleared:

• Monitor serum creatinine and eGFR as already recommended for tenofovir therapy 6, 7
• Tenofovir (especially TDF) can cause renal dysfunction requiring dose adjustment 1
• Nitrofurantoin requires dose adjustment in renal impairment and is contraindicated if CrCl <30 mL/min

In summary: Nitrofurantoin can be prescribed, but requires heightened vigilance for hepatotoxicity in this population, particularly with prolonged use. Short courses for acute UTI are generally safe with appropriate monitoring.